Document is current

Article History

Received: 3 December 2024

Accepted: 21 January 2025

First Online: 28 March 2025

Declarations

:

: John R Ingram: Receives a stipend as Editor‑in‑Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate; consultant for AbbVie, Boehringer Ingelheim, ChemoCentryx, Citryll, MoonLake, Novartis, UCB, and Union Therapeutics, and has served on advisory boards for Insmed, Kymera Therapeutics and Viela Bio; co‑copyright holder of HiSQOL©, patient global assessment, and HS-IGA; his department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. Jérémy Lambert, Valerie Ciaravino, Robert Rolleri, Ingrid Pansar, Luke Peterson: Employees and shareholders of UCB. Christopher G Pelligra: Employee of Evidera, a part of ThermoFisher Scientific that receives funding for research from UCB. Linnea Thorlacius: Received speaker honoraria from UCB and is co‑copyright holder of HiSQOL© and HS-IGA.

: The study protocol, amendments, and patient informed consent were reviewed by a national, regional, or Independent Ethics Committee (IEC) or Institutional Review Board (IRB). This study was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved.